
|Articles|October 17, 2012
FDA approves treatment for cystinosis
The FDA has approved cysteamine ophthalmic solution (Cystaran, Sigma-Tau Pharmaceuticals) 0.44% for corneal cystine crystal accumulation in patients with cystinosis.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Seeing the difference: Multimodal imaging for AMD and GA
2
Spotlight on women's health: Understanding thyroid eye disease
3
NCX 470 advances toward US, China NDA submissions for NCX 470
4
FDA extends Aldeyra's reproxalap PDUFA after requesting additional clinical study report
5








































